ClinicalTrials.gg
TerminatedNCT01090414Updated Aug 28, 2019Results posted

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

A Phase 1/2 interventional study of Idelalisib in Chronic Lymphocytic Leukemia and Lymphoma, Non-Hodgkin, sponsored by Gilead Sciences. Terminated at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by Gilead Sciences · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
202
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
7th of 25
202 · median 102
Started
2010
with 1 other
Phase 1/2
2 of 25
none open now
Registered
2nd of 25
by date
Lead sponsor
19 of 25
Gilead Sciences

Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 7th largest by enrollment, is one of 2 that started in 2010, is one of 2 in phase 1/2, and was the 2nd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This is a long-term safety extension study of idelalisib (GS-1101; CAL-101) in patients with hematologic malignancies who complete other idelalisib studies. It provides the opportunity for patients to continue treatment as long as the patient is deriving clinical benefit. Patients will be followed according to the standard of care as appropriate for their type of cancer. The dose of idelalisib will generally be the same as the dose that was administered at the end of the prior study, but may be titrated up to improve clinical response or down for toxicity. Patients will be withdrawn from the study if they develop progressive disease, unacceptable toxicity related to idelalisib, or if they no longer derive clinical benefit in the opinion of the investigator.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Lymphoma, Non-Hodgkin

Keywords

  • Idelalisib
  • Chronic lymphocytic leukemia (CLL)
  • Non-Hodgkin lymphoma (NHL)
  • Phosphatidylinositol 3-kinase (PI3K)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients with hematologic completing a prior idelalisib study with a clinical benefit are eligible
  • Women of must have a negative pregnancy test to be eligible
  • Male patients, and female patients of childbearing potential, must agree to use method(s) of specified in the protocol

Key Exclusion Criteria:

  • Patients who are unwilling or unable to comply with the protocol are not eligible

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Idelalisib

    Participants will receive up to 350 mg of idelalisib twice daily until disease progression or unacceptable toxicity.

    Drug: Idelalisib

Interventions

  • Idelalisib tablets or capsules administered orally

    Also known as: Zydelig®, GS-1101, CAL-101

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Overall response rate (ORR) was defined as the percentage of participants who achieve complete response (CR), partial response (PR), or minor response (MR; for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM) only).

    Time frame: Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)

  2. Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events

    Time frame: Parent study baseline to end of study 101-99 (maximum: up to 91.2 months) plus 30 days

Secondary outcomes

  1. Duration of Response

    Duration of response (DOR) was defined as the interval from the first documentation of CR, PR, or MR (for LPL/WM) to the earlier of the first documentation of disease progression or death from any cause. DOR was analyzed using Kaplan-Meier (KM) estimates.

    Time frame: Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)

  2. Progression-Free Survival

    Progression-free survival (PFS) was defined as the interval from start of idelalisib treatment in the parent study to the earlier of the first documentation of disease progression or death from any cause. PFS was analyzed using KM estimates.

    Time frame: Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)

  3. Overall Survival

    Overall survival (OS) was defined as the interval from the start of study treatment in the parent study to death from any cause. OS was analyzed using KM estimates.

    Time frame: Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)

  4. Time to Response

    Time to response (TTR) was defined as the interval from start of study treatment to the first documentation of CR, PR, or MR (for LPL/WM). Analysis only includes participants who achieved complete or partial response (or minor response for LPL/WM participants). No participants in the 101-02 (AML and MM) groups achieved a complete or partial response.

    Time frame: Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)

07

Results

Posted Aug 28, 2019

Participant flow

Participants were enrolled at study sites in the United States. The first participant was screened on 22 March 2010. The last study visit occurred on 18 June 2018.

Parent Studies
Participant flow — Parent Studies
Milestone101-02101-07101-08101-10
Started1912416418
Completed50114435
Not completed1411272113
Study 101-99
Participant flow — Study 101-99
Milestone101-02101-07101-08101-10
Started48108415
Completed0000
Not completed48108415
Withdrew: Progressive disease2848104
Withdrew: Adverse event1028180
Withdrew: Investigator request11140
Withdrew: Death3810
Withdrew: Sponsor discontinued study0750
Withdrew: Other (unknown reasons)3300
Withdrew: Withdrew consent0231
Withdrew: Participant request3100

Outcome measures

PrimaryOverall Response Rate

Overall response rate (ORR) was defined as the percentage of participants who achieve complete response (CR), partial response (PR), or minor response (MR; for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM) only).

Time frame:
Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participants101-02 (AML)101-02 (CLL)101-02 (DLBCL)101-02 (iNHL)101-02 (MCL)101-02 (MM)101-07 (CLL)101-07 (iNHL)101-07 (MCL)101-08 (CLL or SLL)101-10 (iNHL)
Overall Response Rate0 (0 to 0)57.4 (43.2 to 70.8)11.1 (0.3 to 48.2)48.4 (35.8 to 61.3)40.0 (24.9 to 56.7)0 (0 to 0)81.7 (73.5 to 88.3)82.6 (72.9 to 89.9)57.5 (40.9 to 73.0)96.9 (89.2 to 99.6)44.4 (21.5 to 69.2)
PrimaryPercentage of Participants Who Experienced Any Treatment-Emergent Adverse Events
Time frame:
Parent study baseline to end of study 101-99 (maximum: up to 91.2 months) plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events
percentage of participants101-02101-07101-08101-10
Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events98.498.8100.094.4
SecondaryDuration of Response

Duration of response (DOR) was defined as the interval from the first documentation of CR, PR, or MR (for LPL/WM) to the earlier of the first documentation of disease progression or death from any cause. DOR was analyzed using Kaplan-Meier (KM) estimates.

Time frame:
Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)
Reported as:
Median · Months
Duration of Response
Months101-02 (AML)101-02 (CLL)101-02 (DLBCL)101-02 (iNHL)101-02 (MCL)101-02 (MM)101-07 (CLL)101-07 (iNHL)101-07 (MCL)101-08 (CLL or SLL)101-10 (iNHL)
Duration of ResponseNA (NA to NA)21.2 (8.1 to 30.4)NA (NA to NA)18.4 (10.9 to 32.4)2.7 (1 to 8.1)NA (NA to NA)26.6 (18.5 to 44.1)42.9 (20.5 to 83.3)9.3 (5.6 to 37.5)63.8 (54.0 to NA)14.4 (6.6 to 46.3)
SecondaryProgression-Free Survival

Progression-free survival (PFS) was defined as the interval from start of idelalisib treatment in the parent study to the earlier of the first documentation of disease progression or death from any cause. PFS was analyzed using KM estimates.

Time frame:
Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)
Reported as:
Median · Months
Progression-Free Survival
Months101-02 (AML)101-02 (CLL)101-02 (DLBCL)101-02 (iNHL)101-02 (MCL)101-02 (MM)101-07 (CLL)101-07 (iNHL)101-07 (MCL)101-08 (CLL or SLL)101-10 (iNHL)
Progression-Free Survival0.9 (0.4 to 1)15.8 (5.6 to 39.6)1.5 (0.3 to 4.1)7.6 (3.7 to 17.7)3.7 (2.7 to 8.2)1 (0.9 to 1.8)26.1 (19.0 to 36.8)32.8 (22.0 to 81.3)11.1 (3.4 to 12.9)65.6 (55.8 to NA)10.2 (2.8 to 19.1)
SecondaryOverall Survival

Overall survival (OS) was defined as the interval from the start of study treatment in the parent study to death from any cause. OS was analyzed using KM estimates.

Time frame:
Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)
Reported as:
Median · Months
Overall Survival
Months101-02 (AML)101-02 (CLL)101-02 (DLBCL)101-02 (iNHL)101-02 (MCL)101-02 (MM)101-07 (CLL)101-07 (iNHL)101-07 (MCL)101-08 (CLL or SLL)101-10 (iNHL)
Overall SurvivalNA (NA to NA)NA (39.7 to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)5.2 (1.2 to 5.2)NA (50.2 to NA)NA (NA to NA)NA (NA to NA)NA (66.3 to NA)NA (10.3 to NA)
SecondaryTime to Response

Time to response (TTR) was defined as the interval from start of study treatment to the first documentation of CR, PR, or MR (for LPL/WM). Analysis only includes participants who achieved complete or partial response (or minor response for LPL/WM participants). No participants in the 101-02 (AML and MM) groups achieved a complete or partial response.

Time frame:
Parent study baseline to end of study 101-99 (maximum: up to 91.2 months)
Reported as:
Median · Months
Time to Response
Months101-02 (AML)101-02 (CLL)101-02 (DLBCL)101-02 (iNHL)101-02 (MCL)101-02 (MM)101-07 (CLL)101-07 (iNHL)101-07 (MCL)101-08 (CLL or SLL)101-10 (iNHL)
Time to Response—1.9 (1.0 to 7.5)4.0 (4.0 to 4.0)1.3 (1.0 to 3.7)1.1 (1.0 to 1.9)—1.9 (1.9 to 1.9)1.9 (1.9 to 3.0)1.9 (1.9 to 2.0)1.9 (1.9 to 1.9)2.7 (2.6 to 3.1)

Adverse events

Collected over First dose date in parent study to end of study 101-99 (maximum: up to 91.2 months) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
101-0225/191 (13.1%)100/191 (52.4%)183/191 (95.8%)
101-0736/241 (14.9%)165/241 (68.5%)236/241 (97.9%)
101-087/45 (15.6%)45/64 (70.3%)63/64 (98.4%)
101-102/6 (33.3%)6/18 (33.3%)16/18 (88.9%)
Most frequent serious events
Showing 10 of 278
Most frequent serious events
Event101-02101-07101-08101-10
ColitisGastrointestinal disorders8/19114/24113/640/18
DiarrhoeaGastrointestinal disorders9/19114/24113/640/18
PneumoniaInfections and infestations30/19140/24112/641/18
PyrexiaGeneral disorders6/19131/2413/640/18
Tumour lysis syndromeMetabolism and nutrition disorders0/1914/2410/642/18
Renal failureRenal and urinary disorders3/1910/2410/642/18
Febrile neutropeniaBlood and lymphatic system disorders12/19123/2413/640/18
SepsisInfections and infestations4/19114/2411/641/18
Atrial fibrillationCardiac disorders0/1913/2410/641/18
Gastrointestinal haemorrhageGastrointestinal disorders1/1912/2410/641/18
Most frequent other events
Showing 10 of 132
Most frequent other events
Event101-02101-07101-08101-10
DiarrhoeaGastrointestinal disorders58/191106/24136/648/18
FatigueGeneral disorders63/19185/24121/648/18
Alanine aminotransferase increasedInvestigations33/19152/24118/648/18
Aspartate aminotransferase increasedInvestigations35/19147/24118/648/18
NeutropeniaBlood and lymphatic system disorders31/191102/2415/643/18
PyrexiaGeneral disorders49/19192/24126/645/18
NauseaGastrointestinal disorders44/19181/24124/647/18
RashSkin and subcutaneous tissue disorders39/19165/24124/645/18
ChillsGeneral disorders31/19140/24123/642/18
CoughRespiratory, thoracic and mediastinal disorders36/19181/24121/644/18

Baseline characteristics

Data presented includes baseline characteristic data for all participants who received any dose of idelalisib in the parent studies, excluding Cohort 2 participants from Study 101-08 who were not eligible to enroll into Study 101-99.

Age, Customized
Age, Customized(Participants)101-02101-07101-08101-10Total
< 65 years86116013215
≥ 65 years105125645299
Sex: Female, Male
Sex: Female, Male(Participants)101-02101-07101-08101-10Total
Female5276248160
Male1391654010354
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)101-02101-07101-08101-10Total
Hispanic or Latino24017
Not Hispanic or Latino1672346417482
Unknown or Not Reported2230025
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)101-02101-07101-08101-10Total
Race — White1602096112442
Race — Black or African American691521
Race — Asian1111114
Race — Other21104
Race — Not Reported22110033
Diagnosis Status
Diagnosis Status(Participants)101-02101-07101-08101-10Total
Chronic lymphocytic leukemia (CLL)54115590228
Indolent non-Hodgkin lymphoma (iNHL)6486517172
Mantle cell lymphoma (MCL)40400080
Diffuse large B-cell lymphoma (DLBCL)90009
Acute myeloid leukemia (AML)1200012
Multiple myeloma (MM)1200012
Missing00011
08

Study locations

18 sites
  • Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
  • UCLA
    Los Angeles, California 90095-1678, United States
  • Stanford Cancer Center
    Palo Alto, California 94304-5548, United States
  • Center for Cancer & Blood Disorders, PC
    Bethesda, Maryland 20817, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Long Island Jewish medical Center
    New Hyde Park, New York 11042, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • Weill Medical College of Cornell
    New York, New York 10021, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer and Research Center
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Yakima Regional Cancer Care
    Yakima, Washington 98902, United States
  • University of Wisconsin
    Madison, Wisconsin 53792-5156, United States
09

References and documents

Publications

  • Barrientos J, Coutre SE, et al. (2014). Long-Term Follow-Up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine, Bendamustine/Rituximab, Fludarabine, Chlorambucil, or Chlorambucil/Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [Abstract 3343]. 56th American Society of Hematology (ASH) Annual Meeting and Exposition, San Francisco, California.
  • Barrientos JC, Leonard JP, et al. (2013). Update on a Phase 1 Study of the Selective PI3Kδ Inhibitor, Idelalisib (GS-1101) in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory CLL [Presentation]. American Society for Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois.
  • Barrientos JC, Wagner-Johnston ND, et al. (2013). Chemo-Immunotherapy Combination of Idelalisib with Bendamustine/Rituximab or Chlorambucil/Rituximab in Patients with Relapsed/ Refractory CLL Demonstrates Efficacy and Tolerability [Poster 4176]. 55th ASH Annual Meeting and Exposition, New Orleans, Louisiana.
  • Barrientos JC, Sharman J, et al. (2012). GS-1101 (CAL-101), A Selective Phosphatidylinositol 3-Kinase-Delta Inhibitor, in Combination With Ofatumumab for the Treatment of Relapsed/ Refractory CLL [Abstract 1062]. Haematologica: the Hematology Journal 17th Congress of the European Hematology Association 14-17 June 2012 Amsterdam; Netherlands 97 (Suppl 1): 433.
  • Benson D, Kahl BS, et al. (2013). Final Results of a Phase 1 Study of Idelalisib, a Selective Inhibitor of PI3Kδ, in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma [Presentation]. ASCO Annual Meeting, Chicago, Illinois.
  • Brown JR, Cheson BD, et al. (2015). Patterns of Lymphocytosis in Patients with CLL or Small Lymphocytic Lymphoma (SLL) Treated with Idelalisib. 57th ASH Annual Meeting and Exposition, Orlando, Florida.
  • Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May 29;123(22):3390-7. doi: 10.1182/blood-2013-11-535047. Epub 2014 Mar 10. PubMed 24615777 ↗
  • Brown JR, Furman RR, et al. (2013). Final Results of a Phase 1 Study of Idelalisib (GS-1101) a Selective Inhibitor of Phosphatidylinositol 3-Kinase p110 Delta (PI3Kδ) in Patients with Relapsed or Refractory CLL [Presentation]. ASCO Annual Meeting, Chicago, Illinois.
  • Coutre SE, Flinn IW, de Vos S, Barrientos JC, Schreeder MT, Wagner-Johnson ND, Sharman JP, Boyd TE, Fowler N, Dreiling L, Kim Y, Mitra S, Rai K, Leonard JP, Furman RR. Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. Hemasphere. 2018 Apr 25;2(3):e39. doi: 10.1097/HS9.0000000000000039. eCollection 2018 Jun. PubMed 31723767 ↗
  • Coutre S, Barrientos C, et al. (2015). Safety of Idelalisib in B-cell Malignancies: Integrated Analysis of Eight Clinical Trials. ASCO Annual Meeting, Chicago, Illinois.
  • Coutre S, Leonard J, et al. (2015). Idelalisib Monotherapy Results in Durable Responses in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia. ASCO Annual Meeting, Chicago, Illinois.
  • DeVos S, Wagner-Johnston ND, et al. (2014). Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent non-Hodgkin Lymphoma: Phase I/II Results [Abstract 3063]. 56th ASH Annual Meeting and Exposition, San Francisco, California.
  • DeVos S, Furman RR, et al. (2013). Idelalisib, a Selective Inhibitor of PI3Kδ, in Combination with Bendamustine, Fludarabine, or Chlorambucil in Patients with Relapsed or Refractory (R/R) CLL [Poster 2878]. 55th ASH Annual Meeting and Exposition, New Orleans, Louisiana.
  • Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014 May 29;123(22):3406-13. doi: 10.1182/blood-2013-11-538546. Epub 2014 Mar 10. PubMed 24615776 ↗
  • Furman R, DeVos S, et al. (2014). Long-Term Follow-Up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab or Ofatumumab) in Patients with Relapsed or Refractory CLL. 56th ASH Annual Meeting and Exposition, San Francisco, California.
  • Furman R, Sharman J, et al. (2013). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with CLL [Abstract LBA-6]. 55th ASH Annual Meeting and Exposition, New Orleans, Louisiana.
  • Ghia P, Cheson BD, et al. (2016). Patterns of Idelalisib Treatment-Emergent Lymphocytosis in Patients with CLL or SLL [poster]. EHA 21st Congress, Copenhagen, Denmark.
  • Ghia P, Coutre S, et al. (2016). Management of Transaminase Elevations Associated with Idelalisib [poster]. European Hematology Association (EHA) 21st Congress, Copenhagen, Denmark.
  • Gopal AK, Davies AJ, et al. (2015). Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory SLL. 57th ASH Annual Meeting and Exposition, Orlando, Florida.
  • Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014 May 29;123(22):3398-405. doi: 10.1182/blood-2013-11-537555. Epub 2014 Mar 10. PubMed 24615778 ↗
  • Leonard JP, Wagner-Johnston ND, et al. (2013). Combinations of the PI3Kδ Inhibitor Idelalisib (GS-1101) with Rituximab and/or Bendamustine are Tolerable and Highly Active in Patients with Previously Treated, Indolent non-Hodgkin Lymphoma: Updated Results from a Phase I Study [Presentation]. ASCO Annual Meeting, Chicago, Illinois.
  • Martin P, Armas A, et al. (2015). Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL). 57th ASH Annual Meeting and Exposition, Orlando, Florida.
  • O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17;126(25):2686-94. doi: 10.1182/blood-2015-03-630947. Epub 2015 Oct 15. PubMed 26472751 ↗
  • O'Brien SM, Lamanna N, et al. (2014). Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naive Patients ≥ 65 Years with CLL or SLL [Poster 1994]. 56th ASH Annual Meeting and Exposition, San Francisco, California.
  • O'Brien SM, Lamanna N, et al. (2013). A Phase 2 Study of the Selective Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor Idelalisib (GS-1101) in Combination with Rituximab in Treatment-Naive Patients ≥ 65 Years with CLL or SLL [Presentation]. ASCO Annual Meeting, Chicago, Illinois.
  • Spurgeon SE, Wagner-Johnston ND, et al. (2013). Final Results of a Phase 1 Study of Idelalisib, a Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ (PI3Kδ) in Patients with Relapsed or Refractory Mantle Cell Lymphoma [Presentation]. ASCO Annual Meeting, Chicago, Illinois.
  • Wagner-Johnston ND, DeVos S, et al. (2013). Preliminary Results of PI3Kδ Inhibitor Idelalisib (GS-1101) Treatment in Combination with Everolimus, Bortezomib, or Bendamustine/Rituximab in Patients with Previously Treated Mantle Cell Lymphoma [Presentation]. ASCO Annual Meeting, Chicago, Illinois.
  • Wierda W, Coutre S, et al. (2016). Management of Transaminase Elevations in Patients Receiving Idelalisib. ASCO Annual Meeting, Chicago, Illinois.
  • de Vos S, Wagner-Johnston ND, Coutre SE, Flinn IW, Schreeder MT, Fowler NH, Sharman JP, Boccia RV, Barrientos JC, Rai KR, Boyd TE, Furman RR, Kim Y, Godfrey WR, Leonard JP. Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma. Blood Adv. 2016 Nov 30;1(2):122-131. doi: 10.1182/bloodadvances.2016000976. eCollection 2016 Dec 13. PubMed 29296805 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2010 to primary completion in Jun 2018, 98 months.

Results were first posted in Aug 2019, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2010
First posted
Mar 22, 2010
StartActual
Mar 22, 2010
Primary completionActual
Jun 18, 2018
CompletionActual
Jun 18, 2018
Results first posted
Aug 28, 2019
Last update
Aug 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01090414
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 22, 2010
Start date
Mar 22, 2010
Primary completion
Jun 18, 2018
Completion
Jun 18, 2018
Results posted
Aug 28, 2019
Last update
Aug 28, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion